abstract_id,investigational_product,title,modality,indication,phase_number,route_of_administration,mechanism_of_action,target,countries_of_sites,control_arm,treatment_arm,study_population,study_size,component_interventions,regimen_type,line_of_therapy,comparator,trial_design_and_comparator
2271,toripalimab,Neoadjuvant toripalimab plus CapeOX in patients with locally advanced EBV-positive gastric or esophagogastric junction adenocarcinoma (GC/EGJC): Results from the phase II NICE trial.,,locally advanced EBV-positive gastric or esophagogastric junction adenocarcinoma (GC/EGJC),2,,,,,,toripalimab (240 mg) combined with standard-dose CapeOX every 3 weeks for 4 cycles preoperatively and 4 cycles postoperatively,patients with locally advanced EBV-positive gastric or esophagogastric junction adenocarcinoma (GC/EGJC) with clinical tumor stages of cT3-4aNxM0 or cT2N+M0 disease as determined by both imaging scan and staging laparoscopy with negative peritoneal cytology.,Enrolled n=17; analysis set n=16 for resection/MPR/pCR and n=17 for safety; data cut-off Dec 31 2024.,"['toripalimab', 'capecitabine', 'oxaliplatin']",add on,neoadjuvant,,single_arm
1089,ipilimumab and nivolumab,A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma (NEO-GLITIPNI).,,recurrent glioblastoma (rGBM),1,"intravenous, intracerebral, intracavitary",,,,,"2 NEOADJ cycles of IV IPI 1 mg/kg + NIVO 3 mg/kg followed by maximal safe resection (MSR) in week 5 with iCer admin of IPI 5 mg + NIVO 10 mg and iCav admin of IPI 1 mg + NIVO 10 mg. The adjuvant phase consists of biweekly postoperative iCav admin of IPI 1 mg + NIVO 10 mg and IV NIVO 240 mg for 12 cycles, followed by monthly NIVO 480 mg IV maintenance for up to two years.","patients (pts) with resectable rGBM (WHO grade 4, IDH wild type) who progressed after radiotherapy and temozolomide, with a baseline ECOG performance status of 0-2 and ≤8 mg methylprednisolone daily","A total of n=5 patients were enrolled, with a median follow-up of 15 weeks.","['ipilimumab', 'nivolumab']",combination,"recurrent, (neo-)adjuvant",,single_arm
4718,osimertinib plus repotrectinib,Osimertinib plus repotrectinib phase I trial in TKI-resistant non-small cell lung cancer (NSCLC) with EGFR mutations.,,TKI-resistant non-small cell lung cancer (NSCLC) with EGFR mutations,1,,"inhibit Src/FAK/JAK2, in addition to ALK, ROS1 and NTRKs","Src/FAK/JAK2, ALK, ROS1, NTRKs",,,"osimertinib 80mg QD plus repotrectinib in escalating doses: 80mg QD, 160mg QD and 160mg BID.","EGFR-mutant patients resistant to previous lines of treatment, with a median age of 61 years, 60% with PS1, and 48.7% with brain metastasis. The population included treatment-naive patients, osimertinib progressors, and patients who had received two or more previous lines of treatment.","Phase Ia included 15 patients, and Part Ib enrolled 15 patients.","['osimertinib', 'repotrectinib']",combination,resistant to previous lines of treatment,,single_arm
1615,alectinib,"Efficacy and safety of alectinib in pediatric and adult patients with ALK altered advanced solid tumors: Results from the TACKLE phase II trial, a MASTER KEY substudy (NCCH1712/MK003).",tyrosine kinase inhibitor,ALK altered advanced solid tumors,II,orally administered,tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK),anaplastic lymphoma kinase (ALK),,,alectinib as either a capsule or a suspension,"Pediatric and adult patients (aged 8 months to 78 years) with ALK altered (fusion/rearrangements, mutations, or amplifications) locally advanced or metastatic cancer across 11 tumor types.","A total of n=26 patients were treated (main cohort evaluable n=16, all evaluable n=24); median follow-up was 15.0 mo.",['alectinib'],single agent,,,single_arm
42,taxane plus trastuzumab and pertuzumab,"De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.",monoclonal antibody,HER2-positive early breast cancer,3,intravenous,dual HER2 blockade,HER2,,"six 3-week cycles of an investigator-selected taxane (docetaxel, paclitaxel or nab-paclitaxel) plus trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) and pertuzumab (840 mg loading dose, then 420 mg every 3 weeks), with carboplatin (TCbHP; AUC 6 mg/mL per min)","six 3-week cycles of an investigator-selected taxane (docetaxel, paclitaxel or nab-paclitaxel) plus trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) and pertuzumab (840 mg loading dose, then 420 mg every 3 weeks)","Eligible patients were ≥18 years old with untreated, stage II-III, invasive HER2-positive breast cancer.","A total of 774 patients were randomized (n=387 per group) from 15 hospitals, with 766 included in the mITT population (n=382 in THP and n=384 in TCbHP); adjuvant phase follow-up is ongoing.","['taxane', 'trastuzumab', 'pertuzumab']",combination,neoadjuvant,taxane plus trastuzumab and pertuzumab with carboplatin (TCbHP),randomized; taxane + carboplatin + dual HER2 blockade
2242,serplulimab,"Safety, efficacy, and biomarker analysis from a phase II trial of intensive chemotherapy combined with serplulimab and trastuzumab in patients with advanced HER2-positive gastric cancer.",antibody,unresectable locally advanced or metastatic HER2-positive gastric cancer,2,,PD-1... blockade,PD-1,['China'],,"Serplulimab (4.5 mg/kg, D1, Q3W), Trastuzumab (initial 8 mg/kg, D1, then 6 mg/kg, D1, Q3W), and the DOS regimen: oxaliplatin (100 mg/m², IV), docetaxel (40 mg/m², IV), and S-1 (40-60mg, BID, D1-14, Q3W). Chemotherapy is up to 8 cycles. Serplulimab and Trastuzumab can be administered until tumor progression.",patients (pts) with unresectable locally advanced or metastatic HER2-positive gastric cancer,Total recruited n=40 (efficacy-evaluable n=37) from 5 centers in China; median follow-up 7.9 mo.,"['serplulimab', 'trastuzumab', 'oxaliplatin', 'docetaxel', 'S-1']",combination,,,single_arm
4389,osimertinib (osi),Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.,EGFR-TKI,resectable (R) epidermal growth factor-mutated (EGFRm) stage II–IIIB NSCLC,3,oral,"3rd-generation, EGFR-TKI",EGFR,,"placebo (PBO) QD + CT (cis/carboplatin + pemetrexed; 3 cycles, Q3W)","neoadj osi 80 mg QD (≥9 wks) + CT (cis/carboplatin + pemetrexed; 3 cycles, Q3W)",Eligible pts: aged ≥18 yrs; WHO PS ≤1; EGFRm (Ex19del/L858R) stg II–IIIB (AJCC 8th ed) R-NSCLC.,"Overall, 358 pts were randomized: osi + CT n=121, osi mono n=117, PBO + CT n=120; data cut-off: Oct 15, 2024; median EFS follow-up was 16 mo (osi+CT), 18 mo (osi mono), and 19 mo (PBO+CT).","['osimertinib', 'cisplatin', 'carboplatin', 'pemetrexed']",add on,neoadjuvant,CT alone,randomized vs platinum+pemetrexed
4069,KITE-363,A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).,chimeric antigen receptor (CAR) T-cell therapy,relapsed/refractory (R/R) B-cell lymphoma (BCL),1,,"KITE-363 is a bicistronic, autologous CAR T-cell therapy that can potentially prevent CD19 escape through upfront dual targeting of CD19 and CD20.",CD19 and CD20,,,"After lymphodepleting chemotherapy, pts received KITE-363 at dose levels (DLs) 1, 2, or 3 (0.5×10^6, 1×10^6, or 2×10^6 CAR T cells/kg, respectively).","Eligible adults had LBCL, indolent NHL, nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), or mediastinal gray zone lymphoma R/R after ≥2 lines of therapy (LoT). Pts with LBCL may have had primary refractory disease after ≥1 LoT.","As of 10/14/2024, 41 pts were enrolled and 37 received KITE-363 (n=34 with LBCL), with a median follow-up of 7.3 mo.",,single agent,relapsed/refractory after ≥2 lines of therapy,,single_arm
4396,nivolumab plus ipilimumab,Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.,,advanced/relapsed type B3 thymoma or thymic carcinoma (TC),2,infusion,,,,,N 240 mg Q2W and I 1mg/kg Q6W,"patients ≥18yo, with advanced/relapsed type B3 thymoma or thymic carcinoma (TC), after previous exposure to platinum-based chemotherapy.",Enrolled n=56 in 15 centers/5 countries; median follow-up 16.0 mo.,"['nivolumab', 'ipilimumab']",combination,after previous exposure to platinum-based chemotherapy,,single_arm
1850,Anti-CEA CAR-T cells,Safety and efficacy of anti-CEA CAR-T cells to prolong relapse-free survival of colorectal cancer liver metastases patients after radical resection.,cell therapy,prolong relapse-free survival of colorectal cancer liver metastases patients after radical resection,1,infusion,Specific chimeric antigen receptor (CAR) T-cell therapy... Carcinoembryonic antigen (CEA) is a glycoprotein which is highly expressed in colorectal tumor.,Carcinoembryonic antigen (CEA),,,"Three dose levels of 1, 3, and 6 (10^6/kg) Anti-CEA CAR-T cells were administered in a dose-escalating manner.",colorectal cancer liver metastasis patients after radical resection... achieving no evidence of disease status after treatment and had CEA positivity of 30% or greater.,"48 subjects were screened, and 12 received CAR-T cell infusion (n=2 in the 1x10^6/kg group, n=2 in the 3×10^6/kg group, and n=8 in the 6×10^6/kg group); the median follow-up time for 9 pre-infusion relapse-free subjects was 23 mo.",['Anti-CEA CAR-T cells'],single agent,postoperative,,single_arm
3898,cemiplimab,Pilot study evaluating the addition of cemiplimab in BRAF-mutant anaplastic thyroid cancer after progression on dabrafenib and trametinib.,antibody,BRAF-mutant anaplastic thyroid cancer after progression on dabrafenib and trametinib,2,,an antibody to PD-1,PD-1,,,Cemiplimab (Cemi) was added to dabrafenib and trametinib (DT) after any tumor growth on DT.,Single institution pilot study of patients with BRAFm ATC where Cemi was added to DT after any tumor growth on DT (RECIST progression not required). Inclusion criteria included RECIST 1.1 measurable disease and no contraindication to immunotherapy.,n=12 patients received at least one dose of Cemi; data cut-off was 1/15/2025.,"['cemiplimab', 'dabrafenib', 'trametinib']",add on,after progression on dabrafenib and trametinib,,single_arm
3364,nimotuzumab,"Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study.",EGFR antibody,"first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma",3,,"EGFR (epidermal growth factor receptor) antibody, 95% humanization degree",EGFR,,chemotherapy alone,nimo+chemotherapy,"patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma",A total of 118 patients were enrolled: n=55 in the experimental group (nimo+chemotherapy) and n=63 in the control group (chemotherapy alone).,"['nimotuzumab', 'chemotherapy']",add on,first-line,chemotherapy alone,randomized; chemotherapy
5203,nanoliposomal irinotecan,ONITT: A phase I study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors.,nanoliposomal,recurrent or refractory solid tumors,1,intravenous,,,,,"The study evaluated two combinations in separate arms: Arm A consisted of nal-IRI (IV, dose escalated) plus talazoparib (po, 600mcg/m2/dose). Arm B consisted of nal-IRI (IV, dose escalated) plus temozolomide (po, 100mg/m2).",Patients (pts) aged 1-30 with recurrent or refractory solid tumors.,"Forty-six pts enrolled at 5 sites; 37 pts (Arm A n=19, Arm B n=18) were enrolled after a protocol amendment.","['nanoliposomal irinotecan', 'talazoparib', 'temozolomide']",combination,recurrent or refractory,,single_arm
3390,cadonilimab,"Induction cadonilimab combined with chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A multicenter, single-arm, phase II trial.",bi-specific antibody,locally advanced cervical cancer (LACC),2,,a bi-specific antibody targeting both PD-1 and CTLA-4,PD-1 and CTLA-4,,,2 cycles of induction therapy consisting of cadonilimab at a dose of 10mg/kg plus nab-paclitaxel at a dose of 260 mg/m² and cisplatin at a dose of 75mg/m² followed by CCRT,"Eligible patients were women aged 18 years or older, newly diagnosed disease with stage IB3-IVA (International Federation of Gynecology and Obstetrics [FIGO] 2018), with histologically confirmed cervical carcinoma, and had an ECOG performance status of 0 or 1.","Total enrolled n=29 (planned n=29, including n=9 in stage 1), with 26 patients having completed CCRT by the data cut-off of January 19, 2025.","['cadonilimab', 'nab-paclitaxel', 'cisplatin']",combination,Induction therapy for newly diagnosed disease,,single_arm
5097,axitinib + nivolumab,Phase 2 study of axitinib + nivolumab in mucosal melanoma with pilot addition of stereotactic body radiotherapy or ipilimumab in select progressors.,,"untreated, unresectable or advanced Mucosal melanoma (MM)",2/1b,oral (for axitinib),combined VEGF/R and PD-1 blockade,"VEGF/R, PD-1",,,nivolumab (nivo) plus axitinib (axi) 5mg PO twice daily,"patients (pts) with untreated, unresectable or advanced Mucosal melanoma (MM).","N=21 pts were enrolled, n=20 were evaluable for efficacy; doublet arm n=21, triplet arm n=7 (n=5 ipi, n=2 SBRT); median follow up was 15 mos.","['nivolumab', 'axitinib']",combination,untreated,,single_arm
1346,nivolumab and ipilimumab,Efficacy and toxicity of nivolumab and ipilimumab in rare cancer brain metastases: A multi-center basket trial analysis (NCI/SWOG S1609).,checkpoint inhibitors,rare cancer brain metastases,,,dual checkpoint inhibitors,,,,"nivolumab (NIVO, 240 mg Q2W) and ipilimumab (IPI, 1 mg/kg Q6W)",patients with brain metastases (BM) from rare cancers,Total evaluable patients n=684 in the basket trial; analysis compares patients without BM (n=707) and with BM at enrollment (n=20); trial conducted across >1000 sites.,"['nivolumab', 'ipilimumab']",combination,,patients without BM,single_arm
4082,Zilovertamab vedotin (ZV),WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma.,antibody-drug conjugate,relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL),2/3,,novel ROR1-targeting antibody-drug conjugate,ROR1,,,"ZV (1.5, 1.75, or 2.0 mg/kg) plus R-GemOx Q3W for ≥6 cycles","adult participants (pts) with confirmed R/R DLBCL after ≥1 lines of therapy (LOT) who were ineligible for chimeric antigen receptor T-cell therapy (CAR-T), autologous stem-cell transplant (ASCT), or failed such therapies (cohort A).","A total of 40 pts were enrolled in cohort A to receive R-GemOx plus ZV 1.5 mg/kg (n=17), 1.75 mg/kg (n=16), or 2.0 mg/kg (n=7); data cut-off was August 1, 2024; median follow-up was 9.8 mo.","['zilovertamab vedotin', 'rituximab', 'gemcitabine', 'oxaliplatin']",add on,relapsed/refractory after ≥1 lines of therapy,,single_arm
1884,cetuximab,FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab.,monoclonal antibody,metastatic RAS wild-type colorectal cancer (mCRC),III,,anti-EGFR,EGFR,"['German', 'Austrian']",physician’s choice,(FOLF)IRI plus cetuximab,"RAS wild-type (RAS WT) metastatic colorectal cancer (mCRC) pts, who had responded to cetuximab-based induction therapy within FIRE-4 (entry 1) or outside of the study (entry 2).","A total of 672 patients were randomized in the first randomization and 657 were assigned to treatment across 120 German and 10 Austrian centers; within the second randomization, 87 patients were attributed to physician’s choice (n=42) or (FOLF)IRI plus cetuximab (n=45).","['cetuximab', '(FOLF)IRI']",combination,Re-challenge after first-line treatment and second progression,physician’s choice,randomized; physician's choice
49,carboplatin,NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.,,adjuvant therapy of node-positive or high-risk node-negative TNBC,III,IV,,,,dose-dense (DD) AC every 2 weeks for 4 cycles followed by weekly P (80 mg/m2) for 12 doses,dose-dense (DD) AC every 2 weeks for 4 cycles followed by weekly P (80 mg/m2) for 12 doses with carbo AUC of 5 IV every 3 weeks for 4 cycles,patients (pts) with operable node-positive or high-risk node-negative triple-negative breast cancer (TNBC),"769 pts were randomized to control arm (n=385) and carbo arm (n=384); at data cutoff (2/28/25), median follow-up was 79.4 mos.","['doxorubicin', 'cyclophosphamide', 'paclitaxel', 'carboplatin']",add on,adjuvant,doxorubicin/cyclophosphamide (AC) followed by paclitaxel (P),randomized; chemotherapy
3938,sorafenib,Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study.,,AML patients for allogeneic stem cell transplant (allo-SCT),1/2,,,,,,"Sorafenib (up to 800mg) given daily on days -24 to -5, added to a myeloablative conditioning regimen of fludarabine (Flu 40mg/m2 on days -6 to -3) and fractionated busulfan (f-Bu). GVHD prophylaxis was cyclophosphamide 50mg/kg on days 3-4 and tacrolimus, with MMF for unrelated donor graft recipients. Eligible patients could receive sorafenib maintenance for 1 year post-transplant.","59 AML patients aged 18-70 years with 8/8-HLA matched donors. Disease status at SCT was CR1 (71%), CRi (10%), or advanced disease (19%). 58% had ELN22 adverse risk disease, 53% were MRD+, and 29% had FLT3 ITD.","A total of n=59 AML patients were enrolled, with n=3 patients at 200mg, n=3 at 400mg, n=3 at 600mg, and n=50 at 800mg sorafenib; median follow-up in 43 surviving patients was 2.2 years.","['sorafenib', 'fludarabine', 'busulfan']",add on,allogeneic stem cell transplant,,single_arm
3749,alrizomadlin (APG-115),A phase 2 study of novel MDM2 inhibitor alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors.,,advanced adenoid cystic carcinoma (ACC) or other solid tumors,2,oral,MDM2 inhibitor,MDM2,['China'],"Alrizomadlin was administered orally at 50, 100, or 150 mg every other day for 2 weeks, with 1 week off, in repeated 21-day cycles.","alrizomadlin at 50, 100, or 150 mg orally every other day for 2 weeks, with 1 week off, in repeated 21-day cycles, combined with toripalimab 240 mg IV for 30 minutes on Day 1 of repeated 21-day cycles","pts with advanced ACC, malignant peripheral nerve sheath tumor (MPNST), LPS, biliary-tract cancer (BTC), or other solid tumors in China. Enrolled pts had an ECOG PS 0-1 and were without central nervous system metastases.","Total enrolled n=54 (monotherapy arm n=22, combination arm n=32); evaluable n=14 (monotherapy) and n=28 (combination); study conducted in China; data cutoff was January 5, 2025.","['alrizomadlin', 'toripalimab']",single agent and combination,,alrizomadlin monotherapy,single_arm
3626,avelumab plus cetuximab,A phase II (Alliance/A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC).,IgG1 mAb therapy,advanced cutaneous squamous cell carcinoma (cSCC),2,intravenous,IgG1 mAb therapy targeting EGFR and PD-1:PD-(L)1 blockade,"EGFR, PD-(L)1",,avelumab (AV) alone every 2 weeks for up to 2 years (yrs),avelumab (AV) (800 mg) plus cetuximab (C) (500 mg/m2) every 2 weeks for up to 2 years (yrs). C was given for 1 yr in the AV+C arm.,"Eligible patients (pts) had distant metastatic or unresectable locally advanced cSCC, anti-PD-1/PD-L1 mAb naive, no prior cetuximab in the advanced setting, ECOG PS 0-2, HIV+ if CD4 >200 and VL <200.","A total of n=60 patients were enrolled, with n=57 evaluable. Data cutoff was 1/16/25.","['avelumab', 'cetuximab']",combination,advanced cSCC,avelumab alone,randomized vs PD-L1 inhibitor
1946,FOLFOXIRI,Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): The ShorTrip study.,chemotherapy,locally advanced rectal cancer (LARC),2,,,,['Italian'],,short-course radiotherapy (SCRT) followed by one cycle of FOLFOX and 7 cycles of FOLFOXIRI,"Pts ≤70 years with medium-high (5-10 cm from the anal verge) LARC with at least one of the following features: cT4, cN2, involved mesorectal fascia (MRF+) or cT3N+.",Enrolled n=64 in 9 centres; n=63 were resected and evaluated for pathological response.,"['folinic acid', 'fluorouracil', 'oxaliplatin', 'irinotecan']",combination,total neoadjuvant therapy (TNT),,single_arm
2508,recombinant human thrombopoietin (rhTPO),A phase II study of prophylactic thrombopoietin combined with magnetic resonance guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy and concurrent chemotherapy for thoracic esophageal cancer.,recombinant protein,thoracic esophageal cancer (EC) patients treated with concurrent chemoradiotherapy (CRT),2,subcutaneous,,,,,"BM-sparing intensity modulated radiotherapy (BMS-IMRT) (≥45Gy) and concurrent chemotherapy (five cycles of weekly intravenous paclitaxel [50 mg/m²] and cisplatin/nedaplatin [25 mg/m²], or two cycles of intravenous paclitaxel [135-175 mg/m²] and cisplatin [80 mg/m²]), and rhTPO (15000U ih. qw during the radiotherapy).",Thoracic EC patients staged I-IVa (AJCC 7th).,"Planned n=23, screened n=32, enrolled n=27; data from July 20 2023 to June 30 2024.","['recombinant human thrombopoietin', 'paclitaxel', 'cisplatin', 'nedaplatin']",add on,concurrent chemoradiotherapy,historical report,single_arm
6250,5-mg dexamethasone with NEPA,"Single low-dose 5-mg versus 8-mg dexamethasone with NEPA for the 168-h prevention of highly or moderately emetogenic (high-risk patients) chemotherapy-induced nausea/vomiting: An open-label, randomised, controlled, phase 3 trial.",corticosteroid,prevention of highly or moderately emetogenic (high-risk patients) chemotherapy-induced nausea/vomiting (CINV),3,,corticosteroid,,,8 mg DEX treatment arm with NEPA,5 mg DEX treatment arm with NEPA,patients receiving highly or moderately emetogenic (high-risk patients) chemotherapy,Total randomized n=164 assigned to 5 mg or 8 mg DEX treatment arms.,"['Dexamethasone', 'NEPA']",combination,,8-mg dexamethasone with NEPA,randomized vs. dexamethasone + NEPA
2898,lenvatinib plus pembrolizumab,Neoadjuvant lenvatinib plus pembrolizumab for resectable clear-cell renal cell carcinoma (PELUR): A prospective phase 2 study.,"Small molecule, Monoclonal antibody",resectable clear-cell renal cell carcinoma (ccRCC),2,,,,,,neoadjuvant low-dose lenvatinib plus pembrolizumab (ldLP) every 21 days for 3 cycles,patients with resectable high-risk ccRCC,"Enrolled n=33, ITT n=23; median follow-up 22 mo.","['lenvatinib', 'pembrolizumab']",combination,neoadjuvant,,single_arm
1727,RS-0139,Phase 1a dose-escalation study of RS-0139: A novel tumor-targeted nanomedicine for advanced solid tumors.,nanomedicine,advanced solid tumors,1a,intravenously,"RS-0139 is a tumor-targeted prodrug designed to enhance the therapeutic index of docetaxel (DTX) by selectively delivering the active agent to tumor tissues. DTX is covalently bound to a polymer backbone, together with a targeting peptide, which shows a high affinity to αvβ3, αvβ5 and αvβ6 integrin receptors highly overexpressed on the tumor cell surface. Once RS-0139 is up-taken by the cell, the covalent bond is cleaved to release DTX.","αvβ3, αvβ5 and αvβ6 integrin receptors",,,"single dose of RS-0139 intravenously using an accelerated titration design. Dose levels (DL) included 60, 75, and 100 mg/m².","Eligiblepatients (18-75 years) with recurrent, locally advanced, or metastatic solid tumors and ECOG PS 0-1.","Eight patients (n=8) were enrolled across three dose levels (DL 1: 75 mg/m², n=3; DL 2: 100 mg/m², n=2; DL -1: 60 mg/m², n=3).",['RS-0139'],single agent,"recurrent, locally advanced, or metastatic",,single_arm
4318,Isatuximab,Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.,monoclonal antibody,transplant-ineligible newly diagnosed myeloma (Ti NDMM),3,,anti-CD38 monoclonal antibody,CD38,['China'],"VRd (bortezomib, lenalidomide and dexamethasone) as initiation, then Rd (lenalidomide and dexamethasone) as maintenance.","Isa-VRd (Isatuximab plus bortezomib, lenalidomide and dexamethasone) as initiation, then Isa-Rd (Isatuximab plus lenalidomide and dexamethasone) as maintenance.",transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts),"Across the global and China populations, 244 Isa-VRd and 162 VRd pts had PET/CT at baseline; a sub-analysis of patients with plasmacytoma included n=77 for Isa-VRd and n=52 for VRd.","['Isatuximab', 'bortezomib', 'lenalidomide', 'dexamethasone']",add on,front line,"VRd (bortezomib, lenalidomide and dexamethasone)","randomized, bortezomib+lenalidomide+dexamethasone"
3078,apalutamide + abiraterone acetate plus prednisone,Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion.,,PSMA-PET detected metachronous oligometastatic hormone-sensitive prostate cancer (HSPC),2,,ADT+ARPI hormonal blockade,Androgen Receptor,,metastasis-directed SBRT with 10 months of ADT + apalutamide (ADT+APA),metastasis-directed SBRT with 10 months of ADT + apalutamide + abiraterone acetate plus prednisone (ADT+APA+AAP),patients (pts) with PSMA-PET detected metachronous oligometastatic HSPC. Eligible pts had biochemical recurrence or persistence (PSA >0.2) after prostatectomy with metastases treatable within max 3 RT plans.,A total of 36 pts were treated in the combined B2 (n=10) and B2 expansion (n=26) cohorts; median follow-up was 35 months for cohort B2 and 19 months for the B2 expansion.,"['ADT', 'apalutamide', 'abiraterone acetate', 'prednisone']",combination,metachronous oligometastatic,ADT + apalutamide,randomized vs. ADT + ARPI
4854,tislelizumab,"A single-center, prospective, randomized controlled trial of tislelizumab combined with platinum-containing chemotherapy as first-line treatment for HIV-positive patients with advanced non-small cell lung cancer.",PD-1 inhibitor,first-line treatment for HIV-positive patients with advanced non-small cell lung cancer,,,programmed death-1 (PD-1) inhibitors,programmed death-1 (PD-1),['China'],"HIV-negative patients receiving tislelizumab combined with platinum-containing chemotherapy (paclitaxel or nab-paclitaxel or pemetrexed combined with cisplatin or carboplatin) for 4-6 cycles, followed by maintenance therapy with tislelizumab.","HIV-positive patients receiving tislelizumab combined with platinum-containing chemotherapy (paclitaxel or nab-paclitaxel or pemetrexed combined with cisplatin or carboplatin) for 4-6 cycles, followed by maintenance therapy with tislelizumab.",stage IIIC-IV NSCLC patients... divided into HIV-positive and HIV-negative groups based on whether they had HIV infection.,"n=54 enrolled (n=17 HIV-positive, n=37 HIV-negative); median follow-up 7.3 mo (HIV-positive) and 13.4 mo (HIV-negative).","['tislelizumab', 'paclitaxel', 'nab-paclitaxel', 'pemetrexed', 'cisplatin', 'carboplatin']",combination,first-line,HIV-negative patients with advanced NSCLC receiving the same treatment regimen.,randomized vs HIV-negative cohort
2937,sacituzumab govitecan (SG),"First survival outcomes and biomarker results of SURE-01: Neoadjuvant sacituzumab govitecan (SG) monotherapy, followed by radical cystectomy (RC), in patients with muscle-invasive urothelial bladder cancer (MIBC).",antibody-drug conjugate,Neoadjuvant sacituzumab govitecan (SG) monotherapy... in patients with muscle-invasive urothelial bladder cancer (MIBC),2,intravenously,antibody-drug conjugate composed of an anti-trophoblast cell surface antigen 2 (Trop-2) antibody coupled to SN-38 (a topoisomerase-I inhibitor),trophoblast cell surface antigen 2 (Trop-2),,,"4 cycles of SG 7.5 mg/kg intravenously (reduced dose in protocol amendment 1) on days 1 and 8, Q3W, followed by RC","Pts age ≥18 y, ECOG PS 0-1, with histologically confirmed cT2-T4N0M0 MIBC, ineligible/refusing NAC and scheduled for RC","enrolled n=37, efficacy-evaluable n=33; median follow-up 14 mo (range 10-17).",['sacituzumab govitecan'],monotherapy,Neoadjuvant,,single_arm
5240,regorafenib,Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study.,,newly diagnosed multi-metastatic Ewing sarcoma,Ib,oral,,,,,"Regorafenib given orally for 21 days of a 28-day cycle (from day 5) at dose levels from 50 mg/m²/day to 82 mg/m²/day, in combination with standard interval-compressed chemotherapy (VDC/IE).",patients aged 2-50 years with newly diagnosed metastatic (excluding lung/pleura only) Ewing sarcoma,"Thirteen patients (DL0: n=2, DL1: n=11) were enrolled out of a planned maximum of 24 patients across 7 centres and 3 countries, with a data cut-off of 21/01/2025.","['regorafenib', 'VDC/IE chemotherapy']",add on,newly diagnosed,,single_arm
4633,Dato-DXd + rilvegostomig,First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5).,"antibody-drug conjugate, bispecific antibody",First-line (1L) advanced or metastatic non-small cell lung cancer (a/mNSCLC) without actionable genomic alterations (AGAs),1b,intravenous,"Dato-DXd, a TROP2-directed antibody-drug conjugate... Rilvegostomig, a bispecific antibody targeting PD-1 and TIGIT","TROP2, PD-1, TIGIT",,,Dato-DXd (6 mg/kg) + rilvegostomig IV Q3W,treatment-naïve pts with a/mNSCLC without actionable genomic alterations (AGAs),"A total of n=40 patients were treated (C5a, n=20; C5b, n=20), with 20 (50.0%) still on any study treatment at the 24 Oct, 2024 data cut-off; median treatment duration was 5.1 mo.","['datopotamab deruxtecan', 'rilvegostomig']",combination,First-line (1L),,single_arm
1147,nivolumab,Phase 2 study of nivolumab for patients with meningiomas refractory to surgery and radiotherapy with immune-related response criteria.,immunotherapy,meningiomas refractory to surgery and radiotherapy,2,intravenously,,,,,Nivolumab (480 mg) was administered intravenously every 4 weeks and continued until tumor progression or unacceptable toxicity for up to 365 days.,"patients with meningiomas (grade I, II, or III) refractory to surgery and radiotherapy",Planned n=29 (required n=27); total n=29 started therapy; response-evaluable n=28.,['nivolumab'],single agent,refractory to surgery and radiotherapy,,single_arm
9,atezolizumab,Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).,anti-PD-L1 antibody,adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer,3,IV,an anti-PD-L1 antibody,PD-L1,"['NCTN sites', 'German AIO']",mFOLFOX6 alone for 12 cycles,mFOLFOX6 plus atezo (840 mg IV q2 weeks) for 12 cycles (6 months)[mo] followed by atezo monotherapy for 13 cycles (12 mo total),"patients (pts) with surgically resected stage III dMMR colon adenocarcinoma (any T, N1,2 M0), age > 12 years (yr)","A total of 712 patients were randomized to the atezo plus mFOLFOX6 arm (n=355) or the mFOLFOX6 arm (n=357) out of a planned 700, with a median follow-up of 37.2 mo.","['atezolizumab', '5-fluorouracil', 'leucovorin', 'oxaliplatin']",add on,adjuvant,mFOLFOX6 alone,randomized vs chemotherapy
34,aspirin,"Aspirin as secondary prevention for colorectal cancer liver metastases (ASAC): A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.",,secondary prevention for colorectal cancer liver metastases,3,,aspirin may have antineoplastic effects in colon cancer,,"['Norway', 'Sweden', 'Denmark']",placebo once daily for 3 years or until disease recurrence,aspirin 160 mg once daily for 3 years or until disease recurrence,Patients (aged ≥18 years old) radically treated for colorectal cancer liver metastases.,"A total of 466 patients were randomly assigned (aspirin, n=234; placebo, n=232), with 428 patients included in the full analysis set (aspirin, n=217; placebo, n=211) across 14 centers in 3 countries.",['aspirin'],single agent,secondary prevention,placebo,randomized placebo
3637,pembrolizumab,"Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC).",monoclonal antibody,"unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC)",3,intravenous,,,,pbo IV Q3W + CRT (70 Gy in 35 fractions + 3 cycles cisplatin 100 mg/m2 Q3W),17 cycles of pembro 200 mg IV Q3W + CRT (70 Gy in 35 fractions + 3 cycles cisplatin 100 mg/m2 Q3W),Adults with newly diagnosed high-risk unresected LA HNSCC (any T3-T4 [N0-N3] or any N2a-3 [T1-T4] larynx/hypopharynx/oral cavity/p16-negative oropharynx cancers and T4 or N3 p16-positive oropharynx cancer),"402 pts were assigned to each arm (pembro + CRT, n=402; pbo + CRT, n=402); 398 received ≥1 dose of study treatment in each arm. Data cutoff was August 21, 2024, with a median study follow-up of 74.4 mo.","['pembrolizumab', 'cisplatin']",add on,1L,placebo (pbo) plus concurrent chemoradiotherapy (CRT),randomized vs placebo + chemoradiotherapy
2998,BH011,Results of BH011 after intravesical administration in patients with CIS and/or papillary non-muscle invasive bladder cancer (NMIBC) after BCG failure: Interim results from a phase I/II clinical trial.,small molecule,high risk NMIBC (HR NMIBC) after BCG failure,I/II,intravesical,"BH011 is a novel docetaxel formulation for intravesical administration that significantly increased the concentration of free docetaxel and bladder tissue permeability compared to TAXOTERE, which may result in a more efficient and effective tumor response.",,,,"BH011 17.5mg administered intravesically on day 1, once a week for 6 weeks during the induction treatment and once a month for 12 months during the maintenance treatment.","BCG failure (including refractory, recurrence, non-responsive, and intolerant) HR NMIBC pts.","A total of 25 patients were treated (n=7 with CIS, n=18 with papillary tumors), with 24 evaluable for efficacy; median RFS was 20.21 mo.",['docetaxel'],single agent,after BCG failure,,single_arm
5200,olaparib in combination with ceralasertib,Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma.,,recurrent and unresectable osteosarcoma,2,,ATR and PARP inhibitors,ATR and PARP,,,Olaparib 150mg twice a day on days 1-28 and ceralasertib 80mg twice a day on days 1-14 of a 28-day cycle.,"Patients aged 12-40 weighing > 40 Kg with recurrent osteosarcoma and measurable unresectable disease, who had received an average of 4.2 prior therapy regimens.",Planned n=34 evaluable patients for Cohort 1; enrolled n=38 from four centers; evaluable for safety/response/survival n=37; evaluable for primary objective n=33; data cut-off 1/21/2025.,"['olaparib', 'ceralasertib']",combination,recurrent,,single_arm
4416,icotinib,Adjuvant icotinib of 12 months versus observation as adjuvant therapy for completely resected EGFR-mutated stage IB non-small-cell lung cancer: 5-year update from CORIN (GASTO1003).,,adjuvant therapy for completely resected EGFR-mutated stage IB non-small-cell lung cancer (NSCLC),2,,,epidermal growth factor receptor (EGFR),,observation,"icotinib (125mg, three times daily, 12 months)","patients with completely resected, EGFR-mutated, stage IB (7th TNM staging) NSCLC without adjuvant chemotherapy",enrolled n=128 (icotinib n=63; observation n=65); data cut-off December 20 2024; median follow-up 65.0 mo.,['icotinib'],single agent,adjuvant,observation,"randomized, observation"
6060,abemaciclib,"A phase I/II study of abemaciclib, a CDK4/6 inhibitor, in participants with HIV-associated and HIV-negative Kaposi sarcoma.",cyclin-dependent kinase (CDK) inhibitor,HIV-associated and HIV-negative Kaposi sarcoma,I/II,oral,oral cyclin-dependent kinase (CDK) inhibitor that targets CDK4 (cyclin D1) and CDK6 (cyclin D3),CDK4 (cyclin D1) and CDK6 (cyclin D3),,,"abemaciclib 200mg twice daily for days 1-28 of a 28-day cycle, with intra-participant dose reductions permissible for abema-related toxicities.",participants (pts) with HIV-associated and HIV-negative Kaposi sarcoma with a median age of 43 years; eligibility included adherence to antiretroviral therapy in people with HIV (PWH) for > 8 weeks prior to enrollment and no concomitant strong CYP3A4 inhibitors.,"A total of n=34 participants were enrolled, including n=6 in Phase I and n=28 in Phase II (n=17 in Arm 1, n=11 in Arm 2), with n=31 evaluable for response.",['abemaciclib'],single agent,Previously treated and untreated,,single_arm
2468,serplulimab,"Efficacy and safety of second-line therapy with serplulimab, lenvatinib, and paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) for whom immunochemotherapy failed: A multicenter, single-arm, phase II trial (STILL).",PD-1 antibody,second-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) for whom immunochemotherapy failed,2,,PD-1 antibody,PD-1,,,"serplulimab (300 mg), lenvatinib (8 mg QD), and paclitaxel 135-175 mg/m² or nab-paclitaxel 260 mg/m², every 3 weeks for six cycles, followed by maintenance therapy with serplulimab and lenvatinib","Eligible GC/GEJC patients for whom first-line treatments of immunotherapy (IO) and chemotherapy failed, who met at least one of the following 3 criteria: 1) PD-L1 combined positive score (CPS) ≥1; 2) previous partial or complete response, or 3) progression-free survival (PFS) ≥6 months in first-line therapy.",Enrolled n=47 from 8 centers; response-evaluable n=41; median follow-up 6.3 mo.,"['serplulimab', 'lenvatinib', 'paclitaxel']",combination,second-line,,single_arm
2502,tislelizumab,"Preoperative PD-1 inhibitor (tislelizumab) plus SOX for locally advanced gastric or gastro-oesophageal junction cancer: Results from a single-arm, phase II trial.",PD-1 antibody,locally advanced gastric or gastro-oesophageal junction cancer,2,,PD-1 inhibitor,PD-1,,,"three or four preoperative 3-week cycles of SOX plus PD-1 antibody tislelizumab, followed by D2 gastrectomy",Patients with resectable gastric or GEJ cancer clinically staged as cT3N+M0 or cT4NanyM0.,Enrolled n=31; efficacy and safety analysis set n=27.,"['tislelizumab', 'SOX']",add on,preoperative,,single_arm
23,abiraterone,Lower-dose versus standard-dose abiraterone in patients with metastatic castration resistant prostate cancer: A multicentric randomized phase III non-inferiority trial.,hormonal agent,metastatic castration-resistant prostate cancer (mCRPC),3,oral,novel hormonal agent,,,"standard-dose (1000 mg fasting, Arm-B)","lower-dose AbA (250 mg with a low-fat meal, Arm-A)","Patients with metastatic castration-resistant prostate cancer (mCRPC), median age 65 years, ECOG-PS 1 in 68.3%, median of 1 prior treatment line, with 64.0% having received prior docetaxel.","The study recruited n=164 patients (Arm-A n=86; Arm-B n=78) out of a planned n=314, with a median follow-up of 18.1 months.",['Abiraterone Acetate'],single agent,1+ prior lines,standard-dose abiraterone,randomized vs. standard-dose abiraterone
1205,IMC-002,Phase 1b dose extension study of a next-generation anti-CD47 monoclonal antibody IMC-002 combined with lenvatinib in patients with advanced hepatocellular carcinoma (HCC).,monoclonal antibody,advanced hepatocellular carcinoma (HCC),1b,,next-generation anti-CD47 monoclonal antibody... attributed to its unique binding site and distinct mechanism of action.,CD47,,,"IMC-002 was administered at 20 mg/kg Q3W in combination with Lenvatinib, continuing until disease progression.",Eligible pts had advanced HCC that progressed following at least 1 prior systemic therapy and ECOG PS ≤1.,Total n=13; efficacy evaluable n=10.,"['IMC-002', 'lenvatinib']",combination,post at least 1 prior systemic therapy,,single_arm
29,ramucirumab plus pembrolizumab,"PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.",monoclonal antibody,stage IV or recurrent non-small cell lung cancer,3,Intravenous,,,,standard of care (SOC),ramucirumab plus pembrolizumab (RP),"Participants (n=838) with stage IV or recurrent non-small cell lung cancer (NSCLC) who previously received an immune checkpoint inhibitor (ICI) for at least 84 days and platinum-based therapy; median age 68, 29% squamous cell carcinoma, 63% adenocarcinoma, and performance status (PS) of 0-2 (13% PS2).",S2302 enrolled n=838 (n=419/arm); the second interim analysis was based on 370 deaths with a median follow-up for alive patients of 5.2 mos (data cutoff: April 2025).,"['ramucirumab', 'pembrolizumab']",combination,Previously treated with ICI and platinum-based therapy,standard of care,randomized; standard of care
2254,abemaciclib and ramucirumab,Multicenter phase I/II study of abemaciclib and ramucirumab in metastatic gastroesophageal adenocarcinoma (GEA): CDK4/6 and cyclin D1 alterations as a predictor of response and survival.,,metastatic gastroesophageal adenocarcinoma (GEA),I/II,"oral, intravenous",CDK4/6 inhibition,CDK4/6 and Cyclin D1,,,abemaciclib (A) (150mg po bid) and ramucirumab (RAM) (8mg/kg iv every 2 weeks),"Pretreated advanced GEA (2nd or 3rd line) patients with a median age of 61.5 years, mostly male (18/20), ECOG performance status of 0 in 40%, and 55% having received prior immunotherapy with 1st line chemotherapy.",Enrolled n=20 (planned n=30); evaluable for biomarkers n=17.,"['abemaciclib', 'ramucirumab']",combination,2nd or 3rd line,,single_arm
4492,adebrelimab,"A prospective, single-arm, phase II trial of adebrelimab plus nab-paclitaxel and carboplatin in patients with unresectable advanced metastatic or recurrent thymic carcinomas.",monoclonal antibody,unresectable advanced metastatic or recurrent thymic carcinomas,II,intravenous,,PD-L1,,,"adebrelimab (20 mg/kg) plus nab-paclitaxel (260 mg/m2) and carboplatin (AUC 5) every 3 weeks for up to 4-6 cycles, followed by adebrelimab (20 mg/kg) every 3 weeks for up to 2 years until progression or unacceptable toxicity","patients with unresectable UICC stage III or IV, recurrent, or metastatic TCs without any previous anti-tumor therapy","A total of n=18 patients were enrolled in the first stage and included in the efficacy and safety analysis, with a planned expansion to n=33; data cut-off was Dec 1, 2024.","['adebrelimab', 'nab-paclitaxel', 'carboplatin']",add on,first-line,,single_arm
